Key Features & Benefits
Clinically relevant – Recapitulates human ITP with autoantibody-mediated platelet destruction via Fcγ receptor-mediated phagocytosis.
Quantifiable endpoint – Platelet count (PLT) measurement via automated hematology analyzer or flow cytometry.
Flexible and tunable – Acute or chronic ITP models by single or repeat antibody administration; dose escalation for prolonged thrombocytopenia.
Multiple strains – CD1 (outbred) and C57BL/6 (inbred) models available to suit different experimental needs.
Translational value – Ideal for testing thrombopoietin receptor agonists (eltrombopag, romiplostim), Fc receptor blockers (fostamatinib), and immunomodulators (IVIG, anti-CD20).
IND-ready data packages – Studies can be conducted in accordance with GLP principles.
Technical Data & Validation
2OA-BSA Induced C57BL/6 mice PBC Model
Applications
• Efficacy testing of thrombopoietin receptor agonists (eltrombopag, romiplostim, avatrombopag)
• Evaluation of Fc receptor blockers (fostamatinib, efgartigimod) and complement inhibitors
• Testing of immunomodulators (IVIG, anti-CD20, anti-CD40L) and spleen tyrosine kinase (Syk) inhibitors
• Target validation for platelet clearance and autoimmune pathways
• IND-enabling pharmacology and toxicology studies
Model Specifications
| Parameter | CD1 Mouse ITP Model | C57BL/6 Mouse ITP Model |
| Species/Strain | CD1 mouse (outbred) | C57BL/6 mouse (inbred) |
| Induction method | Intravenous injection of anti-CD41 monoclonal antibody (e.g., MWReg30, 0.5–10 μg/g) – single dose for acute ITP, repeat doses for chronic ITP |
| Study duration | Acute: 1–7 days; Chronic: 2–4 weeks (repeat dosing) | Acute: 1–7 days; Chronic: 2–4 weeks (repeat dosing) |
| Key endpoints | Platelet count (PLT) via hematology analyzer, bleeding time, survival, optional: splenic histopathology, macrophage phenotyping |
| Positive control | IVIG (intravenous immunoglobulin) or eltrombopag available as reference compounds |
| Data package | Raw data, analysis reports, hematology results, bioinformatics (optional) |
❓ Frequently Asked Questions
Q: How does anti-CD41 antibody induce thrombocytopenia?
A: Anti-CD41 antibodies bind to platelet surface glycoprotein IIb (integrin αIIb), opsonizing platelets. Fcγ receptors on splenic macrophages recognize the antibody-coated platelets, leading to Fc-mediated phagocytosis and rapid clearance from circulation, mimicking human ITP pathogenesis.
Q: What are the differences between CD1 and C57BL/6 ITP models?
A: CD1 mice are outbred, providing greater genetic diversity, useful for modeling patient variability. C57BL/6 are inbred, offering consistency and compatibility with transgenic and knockout strains, ideal for mechanistic studies.
Q: Can this model be used for IND-enabling studies?
A: Yes. Studies can be conducted in accordance with GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different antibody doses, single vs. repeat dosing, prophylactic vs. therapeutic treatment)?
A: Absolutely. Our scientific team tailors anti-CD41 antibody doses, dosing schedules (acute or chronic), and treatment timing to your specific drug candidate.
Q: What is the typical timeline for a pilot efficacy study?
A: Acute ITP studies are typically completed within 7 days post-antibody administration. Chronic ITP studies may run 2–4 weeks with repeat dosing and multiple platelet count assessments.
